A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups
Study Contact Information:
For additional information, please contact: Cindy Callahan, RN by email or Susanne Glantz by email.
About the Study
This study will validate and evaluate the performance of the IMMray PanCan-d test for pancreatic cancer diagnosis in comparison to standard of care imaging currently used in pancreatic cancer disease surveillance by the research sites’ institutions.
ENROLLMENT HAS CLOSED FOR THIS STUDY!
Type of Study
This study will enroll people who do not have pancreatic cancer, but have a higher risk of developing the disease. This is a prospective study, which will watch participants for development of pancreatic cancer over time.
What the Study Entails
- Participants will have blood samples taken and tested using the IMMray PanCan-d test.
- Participants will also undergo imaging and doctors visits consistent with the research site's pancreatic cancer screening program.
- The analysis will compare IMMray PanCan-d test results for each subject to corresponding imaging assessments performed as part of standard of care pancreatic screening surveillance.
- Any subject who shows evidence of disease while on-study will be removed from the study to receive standard of care per the hospital's guidelines.
- New Haven, CT: Yale University
- Chicago, IL: University of Chicago Medical Center
- Boston, MA: Massachusetts General Hospital
- Worcester, MA: University of Massachusetts
- New York
- New York, NY: New York University Hospital
- New York, NY: Columbia University
- New York, NY: Mount Sinai Hospital
- Portland, OR: Oregon Health & Science University
- Philadelphia, PA: University of Pennsylvania
- Pittsburgh, PA: University of Pittsburgh Medical Center
- Contact: Randall Brand by email
- Montreal: The Research Institute of the McGill University Health Centre
Other international sites are open in the following countries:
- United Kingdom
Study Director: Rolf Ehrnström Immunovia, Inc.
This Study is Open To:
This Study is Not Open To:
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.